|
Title
|
Published
|
Price
|
|
Current and Future Therapies for Colorectal Cancer
By: BioSeeker Group AB
Executive Summary
Introduction
Colorectal cancer (CRC) is the second most common cause of cancer death in much of the developed world. Cancer-related mortality is slowly decreasing as a result of better detection and significant
|
more...
|
9/19/2005
|
$2,730.00
|
|
CRC Drug Pipeline Update 2005
By: BioSeeker Group AB
Executive Summary
Colorectal cancer (CRC) is the third most common form of cancer worldwide and the second-leading cause of malignancy-related death in the United States. Although treatment options have increased over the last years, the
|
more...
|
8/25/2005
|
$1,979.00
|
|
Melanoma Therapeutics: Which Strategy Will Take Us There?
By: BioSeeker Group AB
This report covers the latest on:
Disease overview, including incidence, unmet needs, risk factors, screening and diagnosis.
Analysis of current treatment and key therapeutic strategies, including surgery, immunotherapy, vaccines and combination therapies.
Includes
|
more...
|
7/18/2005
|
$1,715.00
|
|
Analytical Tool - Analysis of Melanoma R&D: The Complete Guide
By: BioSeeker Group AB
Executive Summary
"Analysis of Melanoma Cancer R&D - the Complete Guide" offers a unique tool for analysing the vast amount of strategic possibilities that have emerged in melanoma R&D. It is at the same time
|
more...
|
6/28/2005
|
$5,279.00
|
|
Apoptosis: Promise or deception?
By: BioSeeker Group AB
"In this publication of Cancer Highlights, BioSeeker Group analyzes the latest progress made for 25 drug candidates targeting the cell death pathway, apoptosis. Additionally, more early stage candidates are also under investigation, which brings
|
more...
|
5/7/2005
|
$1,365.00
|
|
Analytical Tool - Apoptosis: Promise or deception?
By: BioSeeker Group AB
In this Analytical Tool, BioSeeker Group brings light and understanding of the whole industrial endeavor in apoptosis as cancer therapeutic target. Almost a hundred drug candidates are described in detail and 25 of the most
|
more...
|
5/6/2005
|
$6,402.00
|
|
Business Development and R&D Database: Apoptosis
By: BioSeeker Group AB
Business Development and R&D Database: Apoptosis will provide you with both an update on the latest knowledge and a complete structure on therapeutic companies that are in the process to develop new therapies based on
|
more...
|
5/5/2005
|
$2,574.00
|
|
Basic Platform Report: Apoptosis
By: BioSeeker Group AB
"BioSeeker's ""Basic Platform Report: Apoptosis"" provides a complete and systematic description of the past present and future efforts in cancer R&D, focused on the apoptosis as molecular target. We have, identified, structured and defined information
|
more...
|
5/4/2005
|
$2,574.00
|
|
Analytical Tool - Breast Cancer R&D Comprehensive Guide
By: BioSeeker Group AB
This is BioSeeker Groups second analytical tool to analyze the future competitive situation of breast cancer therapeutics. More updated and extensive, this version pays considerable attention both to the hormone-based therapeutics as well as the
|
more...
|
4/12/2005
|
$7,722.00
|
|
Breast Cancer: The Latest R&D Trends
By: BioSeeker Group AB
In this issue of Cancer Highlights, BioSeeker Group analyzes the most recent advances made for the mid stage to late stage drugs with breast cancer therapy strategies. This extensive highlight will update you on the
|
more...
|
3/22/2005
|
$2,574.00
|
|
Analytical Tool: Cancer Vaccine
By: BioSeeker Group AB
This is BioSeeker Groups second analytical tool in the cancer vaccine field, now more updated and extensive. BioSeeker Group has since several years continuously studied the progress in cancer immunotherapy strategies. So far "passive" immunotherapy
|
more...
|
2/21/2005
|
$8,580.00
|
|
Analytical Tool: Vascular Targeting Agents
By: BioSeeker Group AB
In only a few years time the number of VTA candidates has been doubled, expanding from a handful of drugs to more than twenty. The list of emerging competitors is growing and at least seven
|
more...
|
2/9/2005
|
$9,174.00
|
|
Vascular Targeting Agents: Emerging Competitors
By: BioSeeker Group AB
In this issue of Cancer Highlights, BioSeeker Group analyzes the progress made for vascular targeting agents (VTA). You will receive an update on the most recent advances made for vascular targeting agents that are now
|
more...
|
2/8/2005
|
$1,365.00
|
|
Business Development and R&D Database: Vascular Targeting
By: BioSeeker Group AB
Business Development and R&D Database: Vascular Targeting will provide you with an update on competitors in the field and their recent advances on vascular targeting agents (VTA). In only a few years time the number
|
more...
|
2/1/2005
|
$3,894.00
|
|
Cancer Vaccines Fantasy or Future?
By: BioSeeker Group AB
The concept of utilizing the immune system for the treatment of cancer has been tried for some time without any direct breakthrough success. So far "passive" immunotherapy has experienced most success, with antibody and cytokine
|
more...
|
2/1/2005
|
$1,365.00
|
|
Large Pharma: 2004 a year of progress
By: BioSeeker Group AB
The gross majority of all drugs, which reach late stage of development, are someway or another passed on to the large pharmaceutical companies because they hold the capital needed to conduct the expensive clinical trials
|
more...
|
12/31/2004
|
$1,365.00
|
|
Business Development and R&D Database: Leukemia
By: BioSeeker Group AB
Executive Summary
BioSeeker's Research Unit has released a unique CD-ROM database compiled to enable your independent and unbiased analysis of different areas of leukemia therapeutics progress and pitfalls as well as competition and
|
more...
|
10/26/2004
|
$3,982.50
|
|
Basic Platform Report: Leukemia Therapeutics
By: BioSeeker Group AB
Executive Summary
This "Basic Platform Report: Leukemia Therapeutics" report provides a complete and systematic description of the current R&D activities of already established as well as new innovative therapies for the treatment of leukemia (ALL
|
more...
|
10/26/2004
|
$3,982.50
|
|
Competition on the Future Leukemia Markets
By: BioSeeker Group AB
Leukemia includes a broad variety of histological separate disorders. These make the leukemia market segmented. And even though a high level of unmet medical need, together with its dependence on chemotherapy, leukemia has not historically
|
more...
|
10/26/2004
|
$2,902.50
|
|
Analytical Tool: The Complete Guide to Leukemia Therapeutics
By: BioSeeker Group AB
Executive Summary
Leukemia has not historically been the focus of significant R&D investment for emerging drugs in the pharmaceutical industry. This has now clearly changed with the launch of Novartis' second-line therapy
|
more...
|
10/26/2004
|
$9,174.00
|
|
Swedish Biotech Industry Guide Q3 2004
By: BioSeeker Group AB
Sweden has the fourth largest biotechnology industry in Europe, after Germany, Great Britain, and France. Total revenues of the Swedish Biotech industry amounted to 45 billion SEK in 2001.
This unique CD
|
more...
|
10/26/2004
|
$1,213.65
|
|
Antifungals: 2004 and Beyond
By: BioSeeker Group AB
Executive Summary
The market for antifungal agents continues to grow. According to an article in BioBN, "the worldwide market for treatment of invasive fungal infections is estimated to reach $2.4 billion in 2003 and
|
more...
|
10/19/2004
|
$443.00
|
|
Guide to Venture Capital in European Biopharma
By: BioSeeker Group AB
Executive Summary
If you are managing a biopharma company, raising venture capital can be absolutely critical for the success of your company. The fund raising process should therefore be planned and carried out
|
more...
|
9/14/2004
|
$443.00
|
|
Promising Drug Discovery Tools in Antifungal & Status on Emerging Novel Targets
By: BioSeeker Group AB
The antifungal market is steadily growing and fungal infections is today the third most common hospital-acquired infection. The global market is estimated to be worth more than $3 billion USD. Fungal infections have emerged as
|
more...
|
8/24/2004
|
$443.00
|
|
Market Development in Anti-virals:What is Next?
By: BioSeeker Group AB
There are huge unmet medical needs in viral infections. Any virus can become multi-resistant and a consequence of this is the constant need for new improved pharmaceuticals. The total anti-viral market is progressing well beyond
|
more...
|
8/24/2004
|
$443.00
|
|
Title
|
Published
|
Price
|
(0 items)
